SCYNEXIS, Inc., a biotechnology company, develops medicines to overcome and prevent difficult-to-treat and drug-resistant infections in the United States. It offers BREXAFEMME for the treatment of patients with vulvovaginal candidiasis (VVC) and recurrent VVC. The company's lead product candidate is Ibrexafungerp, a drug for the treatment of invasive candidiasis and/or candidemia, refractory invasive fungal infections, invasive aspergillosis, VVC, and recurrent …
Full SCYX analysis →
Competitive advantage assessment
Key strengths
Operating Leverage in EffectOperating leverage is evident (score 0.91), with margins expanding over time.
Strong Liquidity BufferLiquidity position is strong (score 0.93), providing operational cushion.
Key risks
ROIC Below WACC or PeersROIC at 28.0th percentile suggests inefficient capital deployment.
Revenue Volatility Signals Weak StickinessRevenue volatility is high (stability score 0.07), suggesting weak customer stickiness.
The dashed ring is the peer median. Defense scores are percentile ranks
against peers, so 50 is roughly the typical company in this group.
Upgrade to unlock the signals and evidence behind each defense.
Premium access
Unlock full defense analysis
Get key signals, strengths, and risks for every moat dimension.
Where SCYX ranks in Drug Manufacturers - Specialty & Generic
SCYNEXIS, Inc. ranks #60 of 91
scored companies in Drug Manufacturers - Specialty & Generic by moat score — the top 66%.
The widest moat in the group is Zoetis Inc. (ZTS)
at 85/100.
Moat scores for companies ranked near SCYX in Drug Manufacturers - Specialty & Generic
Pricing power is the ability to raise prices without losing volume.
Cost Advantage
Score 24
· 15% of the moat score
A cost advantage means delivering the same product for structurally less — better purchasing, denser distribution, a more automated process.
Customer Stickiness
Score 17
· 15% of the moat score
Stickiness is what makes revenue repeat without being re-won every year.
Capital Efficiency
Score 20
· 18% of the moat score
Capital efficiency asks what the company earns on the money tied up in the business.
Resilience
Score 55
· 17% of the moat score
Resilience is the capacity to get through a bad year on its own terms — enough liquidity, enough interest cover, and enough cash generation to avoid a rescue financing or a forced sale.
Scale & Market Position
Score 73
· 15% of the moat score
Scale matters only when it converts into economics.
SCYNEXIS, Inc. (SCYX) scores 34 out of 100 on the StatsAlpha Moat Map, which rates its competitive advantage as developing. It ranks #60 of 91 scored companies in Drug Manufacturers - Specialty & Generic, the top 66%. The score is a weighted composite of 6 competitive defenses, each measured against industry peers of 90 companies in Drug Manufacturers - Specialty & Generic. Its strongest defense is Scale & Market Position (73/100) and its weakest is Customer Stickiness (17/100).
How does SCYNEXIS, Inc. compare with other Drug Manufacturers - Specialty & Generic companies?
SCYNEXIS, Inc. ranks #60 of 91 scored companies in Drug Manufacturers - Specialty & Generic by moat score. The widest moat in Drug Manufacturers - Specialty & Generic is Zoetis Inc. (ZTS) at 85/100. The companies ranked closest are Canopy Growth Corporation (CGC) at 35 just above it and Cardiol Therapeutics Inc. (CRDL) at 33 just below it.
How is the moat score calculated?
Each company is scored with an industry-specific template — Corporate Default in this case, chosen because the defenses that matter to a bank are not the ones that matter to a software company. Every defense combines several financial signals, and each signal is measured as a percentile against a peer group of 90 companies in Drug Manufacturers - Specialty & Generic. The defenses are then weighted to produce the overall score out of 100.
Why is SCYNEXIS, Inc. scored with the Corporate Default template?
Most public companies sell a product or a service at a margin, so the moat question is whether that margin survives contact with competitors. The Corporate template scores the six defenses that show up in a general operating company's financial signature: whether it can hold price, produce more cheaply than rivals, keep its customers, earn a return above its cost of capital, withstand a downturn, and turn size into economics.
Which competitive defenses are measured for SCYNEXIS, Inc.?
The Corporate Default template measures 6 defenses, and SCYX scores: Pricing Power (22), Cost Advantage (24), Customer Stickiness (17), Capital Efficiency (20), Resilience (55), Scale & Market Position (73). Each is scored independently as a percentile against peers, so a company can be strong on one and weak on another — the overall score reflects how those defenses are weighted for this industry.
We value your privacy
We use cookies to enhance your browsing experience, analyze site traffic, and personalize content. By clicking 'Accept All', you consent to our use of cookies.
Read our cookie policy
Cookie Preferences
Manage your cookie preferences. Essential cookies are always enabled.